Bevacizumab is used to target VEGF-dependent angiogenesis in patients with platinum-sensitive recurrent ovarian cancer (3) and is also used extensively to treat recurrent disease in patients with glioblastoma who have failed first line therapy (1, 2). Here, VEGFA is linked to ovarian carcinoma.